NCT05421442Completed
A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database
A Nationwide Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the DANBIO Register
Source: ClinicalTrials.gov · Last updated 8 Dec 2025
Brief summary (registry, in English)
The purpose of this study is to expand on the ongoing post-marketing monitoring of abatacept to include all participants with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with abatacept captured in Danish Database for Biologic Therapies (DANBIO).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 38396 (actual)
- First submitted
- 13 Jun 2022
- Start date
- 13 Jun 2019
- Primary completion date
- 22 Aug 2025
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Psoriasis, Psoriatic arthritis, Rheumatoid arthritis
- NCT number
- NCT05421442
What you commit to
- Study type: Observational
- Participants enrolled: 38396
- From 13 Jun 2019 to the primary completion date, 22 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- -Not applicable
Who the study is looking for
- Diagnosis of rheumatoid arthritis (RA) or psoriatic arthritis (PsA)
- Receiving treatment with abatacept
- Receiving treatment with non-targeted DMARD
- Receiving treatment with targeted DMARD
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Lawrenceville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.